by * » Mon Jul 24, 2006 3:38 pm
<br>from an email:<br><br><!--EZCODE QUOTE START--><blockquote><strong><em>Quote:</em></strong><hr><br>BL Fisher Note: And so it begins. The medical profession's obession with forced drug and vaccine use has resulted in a 16 year old boy with cancer being ordered to present himself to medical doctors and be injected with toxic chemicals that could make him sicker or kill him without his voluntary, informed consent. Like the judges in collusion with government officials and medical doctors in the Third Reich or the Gulag, this judge is violating the human right to autonomy and self determination when engaging in medical risk taking. Prostrating himself before MD/Ph.D. hospital officials and self professed "biotethicists" like a supplicant before infallible dieties, this "judge" is violating the human right to voluntary, informed consent to medical interventions that can kill or injure.<br><br><br>When Abraham Cherrix, who has cancer, decided he wanted to pursue an alternative to a second round of chemotherapy and his parents backed his decision up, the medical doctors the family had hired to treat their son complained to government officials in the state's Social Services department. In addition to ordering that Abraham be made a ward of the State and forced to submit to another round of chemotherapy, the judge charged Abraham's parents with neglect for allowing him to pursue an organic food diet and take herbal supplements under the supervision of other doctors using an alternative cancer therapy approach.<br><br><br>A USA Today poll on July 13, 2006 revealed that an overwhelming majority of respondents supported the right of 16 year old Abraham and his parents to make an informed, voluntary decision to choose the kind of health care they want. Now, the majority of respondents to an AOL poll on July 22 say the judge is wrong to force the boy to undergo toxic chemotherapy against his and his parents' will.<br><br><br>Increasingly, medical doctors are inappropriately assuming positions of power within the State and, together with government officials, forcing children and adults to obey their orders even when that order could kill. Abraham's lawyer is right: parents had better think twice before they take their sick children to medical doctors who could take their children from them and harm or kill them with toxic medical therapies. The child could die but the doctors and the judge who gave the order will never spend one hour in prison.<br><br> ______________________<br><br> NVIC E-News is a free service of the National Vaccine Information Center and is supported through membership donations.<br><br>NVIC is funded through the financial support of its members and does not receive any government subsidies. Barbara Loe Fisher, President and Co- founder.<br><br>Learn more about vaccines, diseases and how to protect your informed consent rights <!--EZCODE AUTOLINK START--><a href="http://www.nvic.org">www.nvic.org</a><!--EZCODE AUTOLINK END--><br><br><hr></blockquote><!--EZCODE QUOTE END--><br><br><br><!--EZCODE LINK START--><a href="http://seattlepi.nwsource.com/health/1500AP_Cancer_Drug_Heart_Disease.html?source=mypi">Study: Cancer drug may pose heart danger</a><!--EZCODE LINK END--><br><br>By RANDOLPH E. SCHMID<br>AP SCIENCE WRITER<br><br>WASHINGTON -- A successful cancer-fighting drug may also damage the heart, although a researcher says leukemia patients who need Gleevec should not abandon it.<br><br>While effectively treating cancer, Gleevec can lead to heart failure in some patients, said Dr. Thomas Force, who teaches medicine at Jefferson Medical College of Thomas Jefferson University in Philadelphia.<br><br>His study, published Sunday in the online edition of the journal Nature Medicine, was prompted by reports that 10 patients taking Gleevec for chronic myelogenous leukemia developed severe congestive heart failure.<br><br>Gleevec, sold under the Glivec in some countries, had worldwide sales of $1.2 billion in the first six months of this year, according to the manufacturer, Novartis Pharmaceuticals Corp.<br><br>"Gleevec is a wonderful drug and patients with these diseases need to be on it. It's a lifesaving drug for sure," Force said in a telephone interview.<br><br>"This is not a Vioxx situation," Force added, referring to Merck & Co.'s painkiller that was pulled from the market because of heart side effects.<br><br>Force said he is trying to call attention to the fact that Gleevec and other similar drugs coming along could have significant effects on the heart and that doctors need to be aware of this and watch for symptoms. These patients can be helped with heart treatment, he said.<br><br>Novartis cited the limited data and said further research was needed to better understand the relationship between such studies and their potential impact on monitoring patients who are on the drug.<br><br>The company said in a written statement that the prescribing information with the drug includes data on heart problems. In addition, the drug maker said clinical trials and postmarketing safety data have shown that the incidence of heart failures among people taking drug is "extremely rare."<br><br>Novartis said Force's work does not change "the positive benefit/risk ratio of Glivec for thousands of patients being treated for cancer and other life-threatening diseases."<br><br>Force said the 10 patients with heart failure were taking Gleevec at the University of Texas' M.D. Anderson Cancer Center in Houston and had no heart problems before going on the drug.<br><br>He said doctors took baseline measures of the patients' left ventricular heart function and determined that heart failure developed in these patients between two months and 14 months after they began Gleevec.<br><br>Dr. Jean-Bernard Durand of M.D. Anderson discussed these cases with Force at a meeting and suggested they try to determine the cause of this problem, Force said.<br><br>Gleevec targets three specific proteins, including one called ABL.<br><br>In chronic myelogenous leukemia, genes known as ABL and BCR become fused and produce a hybrid BCR-ABL enzyme that is always active. The overactive BCR-ABL, in turn, drives the excessive proliferation of white blood cells that is the hallmark of leukemia.<br><br>Using viruses that produced for normal ABL and a Gleevec-resistant mutant in laboratory studies and in mice, the researchers found that Gleevec inhibited the normal enzyme but not the mutant, and the mutant ABL "rescued" heart cells from the toxic effects of Gleevec.<br><br>The research was supported by the National Heart, Lung and Blood Institute, the Leukemia and Lymphoma Society, the Finnish Heart Foundation and the Paavo Nurmi Foundation.<br><br>---<br><br><br> <p></p><i></i>